Tag Archive for: Emergent BioSolutions

Emergent BioSolutions announced today it has named former Bausch + Lomb CEO Joseph Papa to the top job as the company, which makes the opioid overdose reversal drug Narcan, aims to return to revenue growth.

Regulatory rejections and clinical trial failures are forcing biopharma companies to restructure in an effort to save costs.

Today the company decided to cut 400 jobs and scale back operations at some its facilities, pivoting its focus on core products such as overdose reversal nasal spray Narcan and anthrax vaccines.

The vaccine, Cyfendus, has been approved for use following suspected or confirmed exposure to a type of bacteria and has to be administered together with antibacterial drugs.

The approval for OTC use of the naloxone-based nasal spray will help align the federal government’s stance with states that have provisions to offer the drug without prescription at pharmacies.

Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc. for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.

Contract drugmaker Emergent Biosolutions said on Tuesday its over-the-counter nasal spray as a treatment for suspected opioid overdose would be reviewed on a priority basis by the U.S. health regulator.

Emergent BioSolutions Inc. said on Friday it had received a warning letter from the U.S. Food and Drug Administration, citing certain deficiencies at the contract drugmaker’s manufacturing facility in Baltimore, Maryland.

Over the weekend, the World Health Organization declared the monkeypox outbreak, so far documented in more than 70 countries, a “public health emergency of international concern [PHEIC].” Here are the initiatives some biopharma companies are taking to contain monkeypox.

British health agencies have secured funding to develop a standardized approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization (WHO) labeled the growing outbreak a global health emergency.